Kennon Heard
Concepts (647)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acetaminophen | 41 | 2025 | 263 | 8.350 |
Why?
| | Chemical and Drug Induced Liver Injury | 16 | 2023 | 138 | 4.670 |
Why?
| | Analgesics, Non-Narcotic | 22 | 2025 | 123 | 4.590 |
Why?
| | Drug Overdose | 32 | 2025 | 363 | 4.000 |
Why?
| | Poison Control Centers | 13 | 2025 | 85 | 3.400 |
Why?
| | Emergency Service, Hospital | 41 | 2023 | 2266 | 3.110 |
Why?
| | Poisoning | 17 | 2017 | 119 | 2.860 |
Why?
| | Acetylcysteine | 12 | 2023 | 141 | 2.540 |
Why?
| | Alanine Transaminase | 14 | 2023 | 147 | 2.500 |
Why?
| | Cocaine | 10 | 2011 | 161 | 2.340 |
Why?
| | Cannabis | 9 | 2020 | 517 | 2.220 |
Why?
| | Prescription Drugs | 9 | 2018 | 111 | 2.140 |
Why?
| | Antidotes | 10 | 2023 | 145 | 1.620 |
Why?
| | Legislation, Drug | 5 | 2017 | 77 | 1.420 |
Why?
| | Analgesics, Opioid | 8 | 2023 | 1135 | 1.410 |
Why?
| | Cysteine | 4 | 2017 | 210 | 1.300 |
Why?
| | Antipsychotic Agents | 7 | 2019 | 185 | 1.290 |
Why?
| | Marijuana Use | 4 | 2021 | 216 | 1.150 |
Why?
| | Medication Errors | 5 | 2015 | 85 | 1.120 |
Why?
| | Pain | 9 | 2020 | 776 | 1.050 |
Why?
| | Emergency Medicine | 6 | 2019 | 259 | 1.040 |
Why?
| | Male | 103 | 2022 | 71570 | 1.040 |
Why?
| | Cocaine-Related Disorders | 5 | 2011 | 128 | 1.030 |
Why?
| | Humans | 156 | 2025 | 143822 | 1.030 |
Why?
| | Drug Packaging | 2 | 2017 | 41 | 1.020 |
Why?
| | Toxicology | 4 | 2021 | 47 | 1.010 |
Why?
| | Medication Reconciliation | 2 | 2016 | 31 | 0.920 |
Why?
| | Female | 96 | 2023 | 77571 | 0.910 |
Why?
| | Dose-Response Relationship, Drug | 16 | 2017 | 2030 | 0.900 |
Why?
| | Adult | 73 | 2022 | 40130 | 0.890 |
Why?
| | Antidepressive Agents, Tricyclic | 5 | 2014 | 31 | 0.850 |
Why?
| | Spider Bites | 5 | 2019 | 7 | 0.850 |
Why?
| | Antivenins | 5 | 2019 | 29 | 0.850 |
Why?
| | Diphenhydramine | 4 | 2023 | 38 | 0.840 |
Why?
| | Akathisia, Drug-Induced | 2 | 2020 | 5 | 0.830 |
Why?
| | Thiazoles | 4 | 2009 | 134 | 0.800 |
Why?
| | Prescription Drug Monitoring Programs | 1 | 2023 | 17 | 0.790 |
Why?
| | Spider Venoms | 4 | 2019 | 11 | 0.790 |
Why?
| | Benzodiazepines | 6 | 2023 | 154 | 0.790 |
Why?
| | Muscarinic Antagonists | 3 | 2023 | 30 | 0.760 |
Why?
| | Lorazepam | 3 | 2023 | 23 | 0.750 |
Why?
| | Heart Arrest | 8 | 2018 | 403 | 0.740 |
Why?
| | Young Adult | 30 | 2020 | 13915 | 0.730 |
Why?
| | Middle Aged | 54 | 2022 | 35631 | 0.710 |
Why?
| | Physostigmine | 2 | 2020 | 13 | 0.710 |
Why?
| | Emergency Treatment | 4 | 2015 | 125 | 0.700 |
Why?
| | Seizures | 6 | 2011 | 454 | 0.700 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2019 | 342 | 0.700 |
Why?
| | Black Widow Spider | 4 | 2019 | 7 | 0.700 |
Why?
| | Medical History Taking | 3 | 2018 | 113 | 0.690 |
Why?
| | Dopamine Uptake Inhibitors | 3 | 2011 | 58 | 0.690 |
Why?
| | Referral and Consultation | 2 | 2020 | 839 | 0.690 |
Why?
| | Decision Support Systems, Clinical | 2 | 2023 | 267 | 0.680 |
Why?
| | Piperazines | 4 | 2009 | 394 | 0.680 |
Why?
| | Delirium | 2 | 2020 | 104 | 0.670 |
Why?
| | Abdominal Pain | 2 | 2019 | 145 | 0.650 |
Why?
| | Anti-Arrhythmia Agents | 4 | 2014 | 137 | 0.630 |
Why?
| | Suicide, Attempted | 5 | 2012 | 380 | 0.630 |
Why?
| | Back Pain | 1 | 2020 | 50 | 0.630 |
Why?
| | Hospitals, Pediatric | 4 | 2018 | 546 | 0.620 |
Why?
| | Vasoconstrictor Agents | 4 | 2009 | 144 | 0.620 |
Why?
| | Free Radical Scavengers | 2 | 2011 | 86 | 0.610 |
Why?
| | Buprenorphine | 2 | 2020 | 182 | 0.600 |
Why?
| | Patient Handoff | 1 | 2020 | 43 | 0.600 |
Why?
| | Haloperidol | 1 | 2019 | 28 | 0.590 |
Why?
| | Retrospective Studies | 31 | 2023 | 16755 | 0.590 |
Why?
| | Ketorolac | 1 | 2019 | 29 | 0.590 |
Why?
| | Emergency Medical Services | 5 | 2025 | 685 | 0.580 |
Why?
| | Social Work | 1 | 2020 | 85 | 0.580 |
Why?
| | Pharmacoepidemiology | 1 | 2018 | 22 | 0.570 |
Why?
| | Gastric Lavage | 3 | 2009 | 9 | 0.560 |
Why?
| | Immunoglobulin Fab Fragments | 4 | 2019 | 55 | 0.550 |
Why?
| | Tertiary Care Centers | 3 | 2017 | 186 | 0.550 |
Why?
| | Vomiting | 6 | 2019 | 130 | 0.550 |
Why?
| | Colorado | 15 | 2021 | 4578 | 0.550 |
Why?
| | Hypotension | 2 | 2022 | 127 | 0.540 |
Why?
| | Prospective Studies | 18 | 2023 | 7900 | 0.530 |
Why?
| | Substance-Related Disorders | 5 | 2012 | 1079 | 0.530 |
Why?
| | Drug Storage | 2 | 2017 | 53 | 0.530 |
Why?
| | Child | 28 | 2023 | 22441 | 0.520 |
Why?
| | Accidents, Home | 1 | 2017 | 33 | 0.520 |
Why?
| | Medical Marijuana | 2 | 2019 | 123 | 0.510 |
Why?
| | Cannabinoids | 3 | 2017 | 178 | 0.510 |
Why?
| | Fibrin Fibrinogen Degradation Products | 2 | 2007 | 93 | 0.500 |
Why?
| | Plant Preparations | 2 | 2015 | 37 | 0.500 |
Why?
| | Pulmonary Embolism | 3 | 2021 | 238 | 0.500 |
Why?
| | Calcium Gluconate | 1 | 2016 | 4 | 0.500 |
Why?
| | Electronic Health Records | 4 | 2024 | 1170 | 0.490 |
Why?
| | Quaternary Ammonium Compounds | 1 | 2016 | 51 | 0.490 |
Why?
| | Hypocalcemia | 1 | 2016 | 38 | 0.480 |
Why?
| | Health Records, Personal | 1 | 2016 | 28 | 0.480 |
Why?
| | Nonprescription Drugs | 4 | 2016 | 65 | 0.470 |
Why?
| | Mobile Applications | 1 | 2018 | 189 | 0.470 |
Why?
| | Blood Proteins | 1 | 2017 | 249 | 0.460 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 5 | 2023 | 258 | 0.460 |
Why?
| | Fat Emulsions, Intravenous | 2 | 2014 | 29 | 0.460 |
Why?
| | Antidepressive Agents | 2 | 2012 | 240 | 0.460 |
Why?
| | Practice Patterns, Physicians' | 3 | 2023 | 1322 | 0.460 |
Why?
| | Prescription Drug Misuse | 1 | 2015 | 50 | 0.450 |
Why?
| | Liver | 6 | 2022 | 1846 | 0.440 |
Why?
| | Electrocardiography | 5 | 2013 | 635 | 0.430 |
Why?
| | Infant | 13 | 2023 | 9886 | 0.430 |
Why?
| | Treatment Outcome | 18 | 2020 | 11460 | 0.430 |
Why?
| | Child, Preschool | 13 | 2018 | 11631 | 0.410 |
Why?
| | Asymptomatic Diseases | 2 | 2013 | 98 | 0.410 |
Why?
| | Crime | 2 | 2011 | 59 | 0.410 |
Why?
| | Observer Variation | 3 | 2010 | 353 | 0.410 |
Why?
| | Energy Drinks | 1 | 2013 | 3 | 0.400 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 1 | 2013 | 25 | 0.400 |
Why?
| | Performance-Enhancing Substances | 1 | 2013 | 11 | 0.400 |
Why?
| | Poisons | 2 | 2023 | 20 | 0.390 |
Why?
| | Arrhythmias, Cardiac | 3 | 2022 | 351 | 0.390 |
Why?
| | Bradycardia | 1 | 2013 | 57 | 0.390 |
Why?
| | Plasmapheresis | 1 | 2013 | 22 | 0.390 |
Why?
| | Diet Surveys | 1 | 2013 | 92 | 0.390 |
Why?
| | Accidents | 1 | 2013 | 44 | 0.390 |
Why?
| | Amphotericin B | 1 | 2013 | 37 | 0.390 |
Why?
| | Adolescent | 27 | 2020 | 22234 | 0.390 |
Why?
| | Hematemesis | 1 | 2012 | 4 | 0.380 |
Why?
| | Double-Blind Method | 7 | 2020 | 2017 | 0.380 |
Why?
| | Aspartate Aminotransferases | 3 | 2010 | 83 | 0.380 |
Why?
| | Phytotherapy | 1 | 2013 | 76 | 0.380 |
Why?
| | Foreign Bodies | 2 | 2011 | 107 | 0.380 |
Why?
| | Stomach Diseases | 1 | 2012 | 20 | 0.380 |
Why?
| | Ethers | 1 | 2012 | 19 | 0.380 |
Why?
| | beta-Alanine | 1 | 2012 | 24 | 0.380 |
Why?
| | Sulfonylurea Compounds | 2 | 2010 | 51 | 0.370 |
Why?
| | Citalopram | 1 | 2012 | 33 | 0.370 |
Why?
| | Liver Function Tests | 7 | 2020 | 99 | 0.370 |
Why?
| | Drug Administration Schedule | 5 | 2014 | 779 | 0.370 |
Why?
| | Antithrombins | 1 | 2012 | 70 | 0.360 |
Why?
| | Propafenone | 1 | 2011 | 2 | 0.360 |
Why?
| | Antifungal Agents | 1 | 2013 | 150 | 0.360 |
Why?
| | Thiophenes | 1 | 2012 | 128 | 0.360 |
Why?
| | Genetic Predisposition to Disease | 1 | 2020 | 2407 | 0.350 |
Why?
| | Anaphylaxis | 2 | 2012 | 102 | 0.350 |
Why?
| | Firesetting Behavior | 1 | 2011 | 1 | 0.350 |
Why?
| | C-Peptide | 2 | 2010 | 188 | 0.350 |
Why?
| | Clinical Enzyme Tests | 2 | 2013 | 10 | 0.350 |
Why?
| | Charcoal | 4 | 2006 | 27 | 0.350 |
Why?
| | Infusions, Intravenous | 6 | 2013 | 427 | 0.350 |
Why?
| | Dronabinol | 4 | 2021 | 247 | 0.350 |
Why?
| | Disease Models, Animal | 9 | 2011 | 4553 | 0.340 |
Why?
| | Benzimidazoles | 1 | 2012 | 187 | 0.340 |
Why?
| | Temperance | 2 | 2010 | 20 | 0.340 |
Why?
| | Alcohol Drinking | 4 | 2012 | 831 | 0.340 |
Why?
| | Aged | 27 | 2019 | 25616 | 0.340 |
Why?
| | Evidence-Based Medicine | 4 | 2023 | 711 | 0.340 |
Why?
| | Chemical and Drug Induced Liver Injury, Chronic | 1 | 2011 | 11 | 0.340 |
Why?
| | Administration, Intravenous | 4 | 2016 | 170 | 0.340 |
Why?
| | Cholinergic Antagonists | 1 | 2011 | 23 | 0.340 |
Why?
| | Brain Edema | 1 | 2011 | 62 | 0.340 |
Why?
| | Opioid-Related Disorders | 2 | 2020 | 582 | 0.340 |
Why?
| | Amitriptyline | 2 | 2001 | 24 | 0.330 |
Why?
| | Blood Chemical Analysis | 3 | 2021 | 110 | 0.330 |
Why?
| | Reproducibility of Results | 6 | 2024 | 3392 | 0.330 |
Why?
| | Self-Injurious Behavior | 1 | 2012 | 136 | 0.330 |
Why?
| | Tachycardia, Ventricular | 1 | 2012 | 177 | 0.330 |
Why?
| | Immunologic Factors | 2 | 2019 | 256 | 0.320 |
Why?
| | Liver Failure | 1 | 2011 | 79 | 0.320 |
Why?
| | Aged, 80 and over | 15 | 2018 | 8130 | 0.320 |
Why?
| | Hydrofluoric Acid | 2 | 2016 | 7 | 0.320 |
Why?
| | Burns | 2 | 2015 | 365 | 0.320 |
Why?
| | Pharmaceutical Vehicles | 1 | 2010 | 12 | 0.320 |
Why?
| | Propylene Glycol | 1 | 2010 | 9 | 0.320 |
Why?
| | Barium | 1 | 2009 | 26 | 0.310 |
Why?
| | Population Surveillance | 1 | 2013 | 491 | 0.310 |
Why?
| | Explosive Agents | 1 | 2009 | 7 | 0.310 |
Why?
| | Time Factors | 12 | 2020 | 7068 | 0.310 |
Why?
| | Imines | 2 | 2022 | 6 | 0.310 |
Why?
| | Hypokalemia | 1 | 2009 | 24 | 0.310 |
Why?
| | Liver Diseases, Alcoholic | 2 | 2007 | 93 | 0.310 |
Why?
| | Acidosis, Lactic | 1 | 2010 | 46 | 0.310 |
Why?
| | United States | 18 | 2025 | 15602 | 0.300 |
Why?
| | Liver Failure, Acute | 2 | 2023 | 54 | 0.300 |
Why?
| | Emetics | 2 | 2006 | 7 | 0.300 |
Why?
| | Warfarin | 1 | 2010 | 165 | 0.300 |
Why?
| | Deception | 1 | 2009 | 18 | 0.300 |
Why?
| | Random Allocation | 3 | 2007 | 364 | 0.300 |
Why?
| | Benzoquinones | 2 | 2022 | 47 | 0.300 |
Why?
| | Iatrogenic Disease | 1 | 2010 | 73 | 0.300 |
Why?
| | Cross-Sectional Studies | 9 | 2020 | 5761 | 0.290 |
Why?
| | Odds Ratio | 7 | 2017 | 1057 | 0.290 |
Why?
| | Surveys and Questionnaires | 4 | 2018 | 6004 | 0.290 |
Why?
| | Risk Assessment | 8 | 2017 | 3556 | 0.290 |
Why?
| | Fluorides | 2 | 2016 | 49 | 0.290 |
Why?
| | Risk Factors | 9 | 2017 | 10623 | 0.290 |
Why?
| | Oximetry | 1 | 2009 | 128 | 0.280 |
Why?
| | Hypothermia, Induced | 1 | 2009 | 95 | 0.280 |
Why?
| | Length of Stay | 3 | 2020 | 1312 | 0.280 |
Why?
| | Cyanoacrylates | 1 | 2008 | 3 | 0.280 |
Why?
| | Eyelashes | 1 | 2008 | 4 | 0.280 |
Why?
| | Adhesives | 1 | 2008 | 15 | 0.270 |
Why?
| | Reference Values | 4 | 2017 | 806 | 0.270 |
Why?
| | Detergents | 1 | 2008 | 44 | 0.270 |
Why?
| | Point-of-Care Systems | 1 | 2010 | 187 | 0.270 |
Why?
| | Intellectual Disability | 1 | 2009 | 176 | 0.270 |
Why?
| | Publishing | 1 | 2009 | 112 | 0.270 |
Why?
| | Hypoglycemia | 2 | 2010 | 473 | 0.270 |
Why?
| | Cardiovascular System | 1 | 2009 | 140 | 0.270 |
Why?
| | Alcoholism | 4 | 2023 | 814 | 0.260 |
Why?
| | Animals | 22 | 2019 | 38140 | 0.260 |
Why?
| | Polyethylene Glycols | 1 | 2012 | 638 | 0.260 |
Why?
| | Brugada Syndrome | 1 | 2007 | 14 | 0.260 |
Why?
| | Niacin | 1 | 2007 | 16 | 0.260 |
Why?
| | Diazepam | 1 | 2007 | 33 | 0.260 |
Why?
| | Clinical Laboratory Techniques | 1 | 2008 | 99 | 0.260 |
Why?
| | Mice, Inbred Strains | 4 | 2009 | 399 | 0.260 |
Why?
| | Vitamin B Complex | 1 | 2007 | 40 | 0.250 |
Why?
| | Pediatrics | 1 | 2015 | 1080 | 0.250 |
Why?
| | Brain Infarction | 1 | 2006 | 23 | 0.250 |
Why?
| | Thromboembolism | 1 | 2007 | 124 | 0.250 |
Why?
| | Specimen Handling | 1 | 2008 | 184 | 0.240 |
Why?
| | Pyrazoles | 2 | 2023 | 499 | 0.240 |
Why?
| | Analgesics | 4 | 2017 | 229 | 0.240 |
Why?
| | Nausea | 4 | 2014 | 111 | 0.240 |
Why?
| | Decontamination | 1 | 2006 | 32 | 0.240 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2006 | 46 | 0.230 |
Why?
| | Amiodarone | 1 | 2005 | 31 | 0.230 |
Why?
| | Self Report | 4 | 2021 | 865 | 0.230 |
Why?
| | Age Factors | 7 | 2017 | 3288 | 0.230 |
Why?
| | Intention | 1 | 2007 | 183 | 0.230 |
Why?
| | Eating | 4 | 2017 | 388 | 0.230 |
Why?
| | Vasospasm, Intracranial | 1 | 2005 | 19 | 0.230 |
Why?
| | Venous Thrombosis | 1 | 2007 | 194 | 0.230 |
Why?
| | Anticoagulants | 1 | 2010 | 718 | 0.230 |
Why?
| | Sodium Nitrite | 1 | 2005 | 39 | 0.220 |
Why?
| | Drug Utilization | 5 | 2014 | 163 | 0.220 |
Why?
| | Epilepsy | 2 | 2020 | 375 | 0.220 |
Why?
| | Calcium | 3 | 2016 | 1181 | 0.220 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2012 | 1688 | 0.220 |
Why?
| | Education, Medical | 2 | 2021 | 270 | 0.220 |
Why?
| | Subarachnoid Hemorrhage | 1 | 2005 | 71 | 0.220 |
Why?
| | Diagnostic Imaging | 1 | 2007 | 334 | 0.220 |
Why?
| | Coma | 2 | 2006 | 36 | 0.220 |
Why?
| | Databases, Factual | 1 | 2010 | 1459 | 0.220 |
Why?
| | Acute Kidney Injury | 1 | 2012 | 848 | 0.220 |
Why?
| | Biomarkers | 7 | 2021 | 4248 | 0.210 |
Why?
| | Hospitals, Urban | 5 | 2021 | 137 | 0.200 |
Why?
| | Injections, Intraperitoneal | 4 | 2009 | 116 | 0.200 |
Why?
| | Anti-Anxiety Agents | 2 | 2020 | 44 | 0.200 |
Why?
| | Triage | 2 | 2025 | 247 | 0.200 |
Why?
| | Animal Experimentation | 1 | 2003 | 8 | 0.200 |
Why?
| | Case-Control Studies | 4 | 2022 | 3614 | 0.200 |
Why?
| | Calcium Chloride | 1 | 2003 | 11 | 0.190 |
Why?
| | Sensitivity and Specificity | 5 | 2010 | 1984 | 0.190 |
Why?
| | Glasgow Coma Scale | 1 | 2004 | 214 | 0.190 |
Why?
| | Hypoglycemic Agents | 2 | 2010 | 1393 | 0.190 |
Why?
| | Insulin | 3 | 2019 | 2502 | 0.190 |
Why?
| | Hospitals, Teaching | 3 | 2014 | 115 | 0.190 |
Why?
| | Fibrinolytic Agents | 2 | 2021 | 285 | 0.190 |
Why?
| | Magnesium Sulfate | 1 | 2003 | 18 | 0.190 |
Why?
| | Documentation | 1 | 2024 | 196 | 0.180 |
Why?
| | Placebos | 2 | 2014 | 192 | 0.180 |
Why?
| | Umbilical Cord | 2 | 2021 | 92 | 0.180 |
Why?
| | Desipramine | 1 | 2001 | 10 | 0.180 |
Why?
| | Longevity | 3 | 2009 | 174 | 0.180 |
Why?
| | Logistic Models | 3 | 2017 | 2095 | 0.180 |
Why?
| | Phenylurea Compounds | 1 | 2022 | 111 | 0.180 |
Why?
| | Confidence Intervals | 4 | 2010 | 330 | 0.170 |
Why?
| | Cardiopulmonary Resuscitation | 3 | 2018 | 337 | 0.170 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2023 | 184 | 0.170 |
Why?
| | Research Design | 3 | 2006 | 1121 | 0.170 |
Why?
| | Severity of Illness Index | 1 | 2009 | 2926 | 0.170 |
Why?
| | Sinus Thrombosis, Intracranial | 1 | 2021 | 24 | 0.170 |
Why?
| | Hyperthermia, Induced | 1 | 2022 | 121 | 0.170 |
Why?
| | Fractures, Bone | 2 | 2017 | 416 | 0.170 |
Why?
| | Heart Atria | 1 | 2001 | 143 | 0.170 |
Why?
| | Narcotic Antagonists | 2 | 2020 | 206 | 0.170 |
Why?
| | Opiate Substitution Treatment | 2 | 2020 | 174 | 0.160 |
Why?
| | Acute Disease | 2 | 2019 | 996 | 0.160 |
Why?
| | Myocardial Contraction | 1 | 2001 | 299 | 0.160 |
Why?
| | Immunoglobulin Fragments | 1 | 1999 | 11 | 0.160 |
Why?
| | Lithium Carbonate | 1 | 1999 | 4 | 0.150 |
Why?
| | Droperidol | 1 | 1999 | 5 | 0.150 |
Why?
| | Lysergic Acid Diethylamide | 1 | 1999 | 3 | 0.150 |
Why?
| | Wisconsin | 1 | 2020 | 99 | 0.150 |
Why?
| | Serotonin Syndrome | 1 | 1999 | 4 | 0.150 |
Why?
| | Starch | 1 | 2019 | 22 | 0.150 |
Why?
| | Scorpion Stings | 1 | 1999 | 1 | 0.150 |
Why?
| | Serotonin Receptor Agonists | 1 | 1999 | 27 | 0.150 |
Why?
| | Nutritive Value | 1 | 2019 | 38 | 0.150 |
Why?
| | Survival Analysis | 4 | 2010 | 1358 | 0.150 |
Why?
| | Healthy Volunteers | 2 | 2019 | 218 | 0.150 |
Why?
| | Ventricular Premature Complexes | 1 | 1999 | 36 | 0.150 |
Why?
| | Thrombocytopenia | 1 | 2021 | 208 | 0.150 |
Why?
| | Snake Bites | 1 | 1999 | 24 | 0.150 |
Why?
| | Geriatric Assessment | 2 | 2011 | 226 | 0.150 |
Why?
| | Immune System | 1 | 2020 | 182 | 0.150 |
Why?
| | Administration, Oral | 4 | 2019 | 841 | 0.150 |
Why?
| | Pregnancy, Tubal | 1 | 1998 | 5 | 0.150 |
Why?
| | Fallopian Tube Diseases | 1 | 1998 | 6 | 0.150 |
Why?
| | Abortifacient Agents, Nonsteroidal | 1 | 1998 | 19 | 0.140 |
Why?
| | Munchausen Syndrome by Proxy | 1 | 1998 | 2 | 0.140 |
Why?
| | Dietary Carbohydrates | 1 | 2019 | 153 | 0.140 |
Why?
| | Community Health Workers | 1 | 2020 | 85 | 0.140 |
Why?
| | Metabolome | 1 | 2022 | 383 | 0.140 |
Why?
| | Drug Therapy, Combination | 4 | 2011 | 1032 | 0.140 |
Why?
| | Plant Extracts | 1 | 2020 | 194 | 0.140 |
Why?
| | Chi-Square Distribution | 2 | 2017 | 516 | 0.140 |
Why?
| | Mass Screening | 1 | 2007 | 1325 | 0.140 |
Why?
| | Cohort Studies | 7 | 2023 | 5862 | 0.140 |
Why?
| | Anticonvulsants | 1 | 2020 | 228 | 0.140 |
Why?
| | Cannabidiol | 1 | 2020 | 134 | 0.140 |
Why?
| | Sex Factors | 5 | 2022 | 2078 | 0.140 |
Why?
| | Sulfasalazine | 1 | 1998 | 21 | 0.140 |
Why?
| | Drug Antagonism | 2 | 2009 | 9 | 0.140 |
Why?
| | Drug Interactions | 4 | 2014 | 398 | 0.130 |
Why?
| | Faculty, Medical | 1 | 2021 | 294 | 0.130 |
Why?
| | Dyspnea | 1 | 1999 | 257 | 0.130 |
Why?
| | Dietary Fats | 1 | 2019 | 314 | 0.130 |
Why?
| | Methotrexate | 1 | 1998 | 239 | 0.130 |
Why?
| | Genome-Wide Association Study | 2 | 2023 | 1446 | 0.130 |
Why?
| | Peptide Fragments | 1 | 2021 | 706 | 0.130 |
Why?
| | Gastrointestinal Agents | 1 | 1998 | 65 | 0.130 |
Why?
| | Continuity of Patient Care | 1 | 2020 | 286 | 0.130 |
Why?
| | Incidence | 4 | 2013 | 2845 | 0.130 |
Why?
| | Out-of-Hospital Cardiac Arrest | 1 | 2018 | 124 | 0.130 |
Why?
| | Survival Rate | 3 | 2013 | 2035 | 0.130 |
Why?
| | Fellowships and Scholarships | 1 | 2021 | 346 | 0.130 |
Why?
| | Ammonium Compounds | 1 | 2016 | 4 | 0.130 |
Why?
| | Mice | 8 | 2009 | 18421 | 0.120 |
Why?
| | Energy Intake | 1 | 2019 | 505 | 0.120 |
Why?
| | Simulation Training | 1 | 2018 | 133 | 0.120 |
Why?
| | Cytochrome P-450 CYP2E1 Inhibitors | 1 | 2016 | 2 | 0.120 |
Why?
| | Prenatal Care | 1 | 2019 | 306 | 0.120 |
Why?
| | Metabolic Clearance Rate | 2 | 2019 | 116 | 0.120 |
Why?
| | Ventricular Fibrillation | 1 | 2016 | 64 | 0.120 |
Why?
| | Half-Life | 2 | 2019 | 150 | 0.120 |
Why?
| | Clinical Trials as Topic | 2 | 2012 | 1047 | 0.120 |
Why?
| | Hypnotics and Sedatives | 1 | 1998 | 215 | 0.120 |
Why?
| | Pharmacovigilance | 1 | 2015 | 23 | 0.120 |
Why?
| | Pain Management | 2 | 2017 | 399 | 0.120 |
Why?
| | Milk | 1 | 2016 | 118 | 0.120 |
Why?
| | Predictive Value of Tests | 3 | 2015 | 2097 | 0.120 |
Why?
| | Genetic Variation | 1 | 2020 | 990 | 0.110 |
Why?
| | Herniorrhaphy | 1 | 2016 | 74 | 0.110 |
Why?
| | Fatal Outcome | 2 | 2013 | 306 | 0.110 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2015 | 80 | 0.110 |
Why?
| | Hemodialysis Units, Hospital | 1 | 1994 | 5 | 0.110 |
Why?
| | Child Behavior | 1 | 2017 | 239 | 0.110 |
Why?
| | Pilot Projects | 1 | 2020 | 1851 | 0.110 |
Why?
| | Ondansetron | 1 | 2014 | 19 | 0.110 |
Why?
| | Total Quality Management | 1 | 1994 | 59 | 0.110 |
Why?
| | Cytochrome P-450 CYP2D6 | 1 | 2014 | 32 | 0.110 |
Why?
| | Models, Biological | 2 | 2015 | 1833 | 0.110 |
Why?
| | Hydrocodone | 1 | 2014 | 19 | 0.110 |
Why?
| | Patient Simulation | 1 | 2014 | 40 | 0.110 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2015 | 98 | 0.110 |
Why?
| | Transaminases | 1 | 2014 | 21 | 0.110 |
Why?
| | Oxycodone | 1 | 2014 | 54 | 0.100 |
Why?
| | Guanfacine | 1 | 2013 | 5 | 0.100 |
Why?
| | Physicians | 2 | 2020 | 932 | 0.100 |
Why?
| | Clonidine | 1 | 2013 | 34 | 0.100 |
Why?
| | Curriculum | 1 | 2021 | 1044 | 0.100 |
Why?
| | Food | 1 | 2015 | 152 | 0.100 |
Why?
| | Vitamins | 1 | 2015 | 177 | 0.100 |
Why?
| | International Normalized Ratio | 2 | 2011 | 47 | 0.100 |
Why?
| | Cesium | 1 | 2013 | 20 | 0.100 |
Why?
| | Acute Pain | 1 | 2014 | 54 | 0.100 |
Why?
| | Internship and Residency | 2 | 2014 | 1245 | 0.100 |
Why?
| | Indazoles | 1 | 2014 | 79 | 0.100 |
Why?
| | Prognosis | 3 | 2011 | 4211 | 0.100 |
Why?
| | Remote Consultation | 1 | 2014 | 66 | 0.100 |
Why?
| | Deoxycholic Acid | 1 | 2013 | 15 | 0.100 |
Why?
| | Pregnancy Complications | 1 | 2019 | 590 | 0.100 |
Why?
| | Lethargy | 1 | 2012 | 4 | 0.100 |
Why?
| | Duloxetine Hydrochloride | 1 | 2012 | 10 | 0.100 |
Why?
| | Pain Measurement | 4 | 2019 | 550 | 0.100 |
Why?
| | Dabigatran | 1 | 2012 | 29 | 0.100 |
Why?
| | Canada | 2 | 2025 | 425 | 0.090 |
Why?
| | Walking | 1 | 2017 | 560 | 0.090 |
Why?
| | Tachycardia | 1 | 2012 | 57 | 0.090 |
Why?
| | Chlorides | 1 | 2013 | 136 | 0.090 |
Why?
| | Sleep Stages | 1 | 2012 | 76 | 0.090 |
Why?
| | Data Collection | 2 | 2013 | 636 | 0.090 |
Why?
| | Sulfhydryl Reagents | 1 | 2012 | 12 | 0.090 |
Why?
| | Marijuana Abuse | 1 | 2015 | 211 | 0.090 |
Why?
| | Attitude of Health Personnel | 1 | 2020 | 1174 | 0.090 |
Why?
| | Mycoses | 1 | 2013 | 88 | 0.090 |
Why?
| | Sampling Studies | 1 | 2012 | 100 | 0.090 |
Why?
| | Arsenicals | 1 | 2012 | 28 | 0.090 |
Why?
| | Dizziness | 1 | 2012 | 94 | 0.090 |
Why?
| | Magnesium | 2 | 2004 | 154 | 0.090 |
Why?
| | Athletic Performance | 1 | 2013 | 76 | 0.090 |
Why?
| | Patient Discharge | 2 | 2016 | 939 | 0.090 |
Why?
| | Information Systems | 1 | 2011 | 59 | 0.090 |
Why?
| | Drug Combinations | 1 | 2013 | 376 | 0.090 |
Why?
| | Immunocompromised Host | 1 | 2013 | 201 | 0.090 |
Why?
| | Sulfides | 1 | 2012 | 91 | 0.090 |
Why?
| | Arabia | 1 | 2011 | 2 | 0.090 |
Why?
| | Levamisole | 1 | 2011 | 20 | 0.090 |
Why?
| | Marijuana Smoking | 1 | 2015 | 257 | 0.090 |
Why?
| | Accidental Falls | 2 | 2011 | 228 | 0.080 |
Why?
| | Hepatic Encephalopathy | 1 | 2011 | 20 | 0.080 |
Why?
| | Follow-Up Studies | 3 | 2010 | 5317 | 0.080 |
Why?
| | Drug Contamination | 1 | 2011 | 51 | 0.080 |
Why?
| | Laparoscopy | 1 | 2016 | 476 | 0.080 |
Why?
| | Structure-Activity Relationship | 1 | 2012 | 567 | 0.080 |
Why?
| | Molecular Structure | 1 | 2012 | 498 | 0.080 |
Why?
| | Dietary Supplements | 1 | 2015 | 576 | 0.080 |
Why?
| | Pharmacogenetics | 1 | 2012 | 170 | 0.080 |
Why?
| | Sports | 1 | 2013 | 213 | 0.080 |
Why?
| | Universities | 1 | 2013 | 452 | 0.080 |
Why?
| | Glipizide | 1 | 2010 | 6 | 0.080 |
Why?
| | Laboratories, Hospital | 1 | 2010 | 12 | 0.080 |
Why?
| | Hepatitis, Alcoholic | 1 | 2010 | 15 | 0.080 |
Why?
| | Troponin | 1 | 2010 | 53 | 0.080 |
Why?
| | Glyburide | 1 | 2010 | 31 | 0.080 |
Why?
| | Crowding | 1 | 2010 | 37 | 0.080 |
Why?
| | Drug Prescriptions | 2 | 2016 | 269 | 0.080 |
Why?
| | Biological Availability | 2 | 2019 | 141 | 0.080 |
Why?
| | Body Weight | 1 | 2014 | 993 | 0.080 |
Why?
| | Adjuvants, Immunologic | 1 | 2011 | 246 | 0.080 |
Why?
| | Watchful Waiting | 1 | 2010 | 86 | 0.080 |
Why?
| | Quetiapine Fumarate | 1 | 2009 | 24 | 0.080 |
Why?
| | Dibenzothiazepines | 1 | 2009 | 16 | 0.080 |
Why?
| | Aripiprazole | 1 | 2009 | 18 | 0.080 |
Why?
| | Risperidone | 1 | 2009 | 28 | 0.070 |
Why?
| | Potassium | 1 | 2009 | 150 | 0.070 |
Why?
| | Role | 1 | 2009 | 29 | 0.070 |
Why?
| | Efficiency, Organizational | 1 | 2010 | 135 | 0.070 |
Why?
| | Head Protective Devices | 1 | 2009 | 24 | 0.070 |
Why?
| | Quality Control | 1 | 2009 | 165 | 0.070 |
Why?
| | Dogs | 1 | 2010 | 437 | 0.070 |
Why?
| | Bibliometrics | 1 | 2009 | 58 | 0.070 |
Why?
| | Acidosis | 2 | 2006 | 105 | 0.070 |
Why?
| | Verapamil | 2 | 2014 | 37 | 0.070 |
Why?
| | Glutathione | 3 | 2022 | 379 | 0.070 |
Why?
| | Renal Dialysis | 1 | 2013 | 459 | 0.070 |
Why?
| | Body Temperature | 1 | 2009 | 223 | 0.070 |
Why?
| | Diarrhea | 1 | 2009 | 188 | 0.070 |
Why?
| | Quality Indicators, Health Care | 1 | 2011 | 308 | 0.070 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2011 | 281 | 0.070 |
Why?
| | Skiing | 1 | 2009 | 49 | 0.070 |
Why?
| | Workload | 1 | 2010 | 167 | 0.070 |
Why?
| | Pharmacy Service, Hospital | 1 | 2009 | 81 | 0.070 |
Why?
| | Bacitracin | 1 | 2008 | 5 | 0.070 |
Why?
| | Hair Preparations | 1 | 2008 | 2 | 0.070 |
Why?
| | Adhesiveness | 1 | 2008 | 19 | 0.070 |
Why?
| | Acetone | 1 | 2008 | 12 | 0.070 |
Why?
| | Propylene Glycols | 1 | 2008 | 27 | 0.070 |
Why?
| | Nylons | 1 | 2008 | 23 | 0.070 |
Why?
| | Equipment Design | 1 | 2009 | 534 | 0.070 |
Why?
| | Informed Consent | 2 | 2006 | 198 | 0.070 |
Why?
| | Cause of Death | 1 | 2010 | 461 | 0.070 |
Why?
| | Withholding Treatment | 1 | 2008 | 79 | 0.070 |
Why?
| | Cellulose | 1 | 2008 | 58 | 0.070 |
Why?
| | Glycerol | 1 | 2008 | 89 | 0.070 |
Why?
| | Drug Synergism | 1 | 2008 | 364 | 0.070 |
Why?
| | Students | 1 | 2013 | 667 | 0.060 |
Why?
| | Nephelometry and Turbidimetry | 1 | 2007 | 15 | 0.060 |
Why?
| | Laboratories | 1 | 2008 | 111 | 0.060 |
Why?
| | Health Services Accessibility | 1 | 2015 | 1078 | 0.060 |
Why?
| | Polypharmacy | 1 | 2008 | 85 | 0.060 |
Why?
| | Tissue Distribution | 2 | 2019 | 328 | 0.060 |
Why?
| | Substance Abuse Detection | 2 | 2021 | 105 | 0.060 |
Why?
| | Phosphates | 1 | 2008 | 179 | 0.060 |
Why?
| | Quinolones | 1 | 2009 | 185 | 0.060 |
Why?
| | Formates | 1 | 2006 | 16 | 0.060 |
Why?
| | Research | 2 | 2011 | 426 | 0.060 |
Why?
| | Military Personnel | 1 | 2014 | 694 | 0.060 |
Why?
| | Periodicals as Topic | 1 | 2009 | 201 | 0.060 |
Why?
| | Defibrillators | 1 | 2006 | 23 | 0.060 |
Why?
| | Combined Modality Therapy | 1 | 2009 | 1261 | 0.060 |
Why?
| | Methanol | 1 | 2006 | 46 | 0.060 |
Why?
| | Kidney Transplantation | 1 | 2013 | 693 | 0.060 |
Why?
| | Vasopressins | 1 | 2006 | 60 | 0.060 |
Why?
| | Statistics, Nonparametric | 1 | 2007 | 431 | 0.060 |
Why?
| | Blindness | 1 | 2006 | 50 | 0.060 |
Why?
| | Probability | 2 | 2010 | 305 | 0.060 |
Why?
| | Health Services for the Aged | 1 | 2006 | 72 | 0.060 |
Why?
| | Spinal Diseases | 1 | 2006 | 51 | 0.060 |
Why?
| | Ipecac | 1 | 2005 | 8 | 0.060 |
Why?
| | Epinephrine | 1 | 2006 | 154 | 0.060 |
Why?
| | Naproxen | 1 | 2006 | 21 | 0.060 |
Why?
| | Respiratory Insufficiency | 1 | 2009 | 333 | 0.060 |
Why?
| | Hospitalization | 2 | 2011 | 2340 | 0.060 |
Why?
| | Population Dynamics | 1 | 2006 | 158 | 0.060 |
Why?
| | Hospitals, University | 1 | 2006 | 175 | 0.060 |
Why?
| | Ibuprofen | 1 | 2006 | 83 | 0.060 |
Why?
| | Haplorhini | 1 | 2005 | 52 | 0.060 |
Why?
| | Aging | 2 | 2014 | 1968 | 0.060 |
Why?
| | Premedication | 1 | 2005 | 42 | 0.060 |
Why?
| | Practice Guidelines as Topic | 2 | 2014 | 1525 | 0.060 |
Why?
| | Geriatrics | 1 | 2006 | 95 | 0.060 |
Why?
| | Telemedicine | 1 | 2014 | 940 | 0.060 |
Why?
| | Risk | 1 | 2007 | 901 | 0.050 |
Why?
| | Respiration, Artificial | 1 | 2009 | 706 | 0.050 |
Why?
| | Spine | 1 | 2006 | 181 | 0.050 |
Why?
| | Water | 1 | 2008 | 470 | 0.050 |
Why?
| | Single-Blind Method | 1 | 2005 | 308 | 0.050 |
Why?
| | Fluoride Poisoning | 1 | 2004 | 3 | 0.050 |
Why?
| | Motivation | 1 | 2009 | 607 | 0.050 |
Why?
| | Phenobarbital | 1 | 2023 | 19 | 0.050 |
Why?
| | Blood Glucose | 2 | 2019 | 2325 | 0.050 |
Why?
| | Guidelines as Topic | 1 | 2005 | 270 | 0.050 |
Why?
| | Hydroxyzine | 1 | 2023 | 3 | 0.050 |
Why?
| | Maltose | 1 | 2023 | 8 | 0.050 |
Why?
| | Resuscitation | 1 | 2006 | 301 | 0.050 |
Why?
| | Health Policy | 1 | 2006 | 390 | 0.050 |
Why?
| | Mycophenolic Acid | 1 | 2004 | 120 | 0.050 |
Why?
| | Delphi Technique | 1 | 2025 | 324 | 0.050 |
Why?
| | Sheep | 1 | 2006 | 871 | 0.050 |
Why?
| | Survival | 1 | 2003 | 38 | 0.050 |
Why?
| | Urea | 1 | 2023 | 84 | 0.050 |
Why?
| | Consensus | 1 | 2025 | 480 | 0.050 |
Why?
| | Patient Participation | 1 | 2006 | 436 | 0.050 |
Why?
| | Aspirin | 1 | 2006 | 389 | 0.050 |
Why?
| | Pregnancy | 3 | 2021 | 7154 | 0.050 |
Why?
| | Lactates | 1 | 2022 | 83 | 0.050 |
Why?
| | Sex Distribution | 2 | 2015 | 379 | 0.050 |
Why?
| | Internet | 1 | 2007 | 699 | 0.050 |
Why?
| | Culture Techniques | 1 | 2001 | 67 | 0.040 |
Why?
| | Urban Population | 2 | 2019 | 485 | 0.040 |
Why?
| | Prevalence | 3 | 2015 | 2819 | 0.040 |
Why?
| | Blood Physiological Phenomena | 1 | 2021 | 12 | 0.040 |
Why?
| | Neural Conduction | 1 | 2001 | 91 | 0.040 |
Why?
| | Hirudins | 1 | 2021 | 52 | 0.040 |
Why?
| | Academic Medical Centers | 2 | 2016 | 537 | 0.040 |
Why?
| | Calcium Channel Blockers | 1 | 2001 | 165 | 0.040 |
Why?
| | Breast Neoplasms | 1 | 2013 | 2497 | 0.040 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2020 | 28 | 0.040 |
Why?
| | Infusions, Parenteral | 1 | 2020 | 43 | 0.040 |
Why?
| | Pirenzepine | 1 | 1999 | 8 | 0.040 |
Why?
| | Scorpions | 1 | 1999 | 3 | 0.040 |
Why?
| | South America | 1 | 1999 | 56 | 0.040 |
Why?
| | Blood Cell Count | 2 | 2013 | 53 | 0.040 |
Why?
| | Narcotics | 1 | 1999 | 54 | 0.040 |
Why?
| | Certification | 1 | 2020 | 119 | 0.040 |
Why?
| | Rupture, Spontaneous | 1 | 1998 | 14 | 0.040 |
Why?
| | Temperature | 1 | 2022 | 681 | 0.040 |
Why?
| | Central Nervous System Depressants | 1 | 1999 | 83 | 0.040 |
Why?
| | Postprandial Period | 1 | 2019 | 114 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2004 | 843 | 0.040 |
Why?
| | Analysis of Variance | 1 | 2001 | 1308 | 0.040 |
Why?
| | Videotape Recording | 1 | 2018 | 37 | 0.040 |
Why?
| | Manikins | 1 | 2018 | 35 | 0.040 |
Why?
| | Sorption Detoxification | 1 | 1998 | 2 | 0.040 |
Why?
| | Ambulatory Care | 1 | 2023 | 592 | 0.040 |
Why?
| | Dietary Proteins | 1 | 2019 | 136 | 0.040 |
Why?
| | North America | 1 | 1999 | 309 | 0.030 |
Why?
| | Cholinesterase Inhibitors | 1 | 1998 | 46 | 0.030 |
Why?
| | Laparotomy | 1 | 1998 | 113 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2021 | 1355 | 0.030 |
Why?
| | Feedback | 1 | 2018 | 182 | 0.030 |
Why?
| | Cardiomyopathies | 1 | 2001 | 333 | 0.030 |
Why?
| | Lipids | 1 | 2022 | 699 | 0.030 |
Why?
| | Triglycerides | 1 | 2019 | 517 | 0.030 |
Why?
| | Maternal Health Services | 1 | 2019 | 102 | 0.030 |
Why?
| | Central Nervous System | 1 | 1999 | 272 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2019 | 594 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2001 | 899 | 0.030 |
Why?
| | Socioeconomic Factors | 2 | 2015 | 1327 | 0.030 |
Why?
| | Bipolar Disorder | 1 | 1999 | 251 | 0.030 |
Why?
| | Registries | 2 | 2010 | 2242 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2019 | 1096 | 0.030 |
Why?
| | Dialysis | 1 | 2015 | 18 | 0.030 |
Why?
| | Hallucinogens | 1 | 2017 | 110 | 0.030 |
Why?
| | Centrifugation | 1 | 2015 | 27 | 0.030 |
Why?
| | Tennessee | 1 | 1994 | 54 | 0.030 |
Why?
| | Observation | 1 | 2014 | 51 | 0.030 |
Why?
| | Hematocrit | 1 | 1994 | 107 | 0.030 |
Why?
| | International Classification of Diseases | 1 | 2015 | 140 | 0.030 |
Why?
| | Syndrome | 1 | 2015 | 373 | 0.030 |
Why?
| | Program Evaluation | 1 | 2018 | 947 | 0.030 |
Why?
| | Anesthetics, Local | 1 | 2014 | 101 | 0.030 |
Why?
| | Warfare | 1 | 2014 | 91 | 0.030 |
Why?
| | Erythropoietin | 1 | 1994 | 99 | 0.030 |
Why?
| | Injections, Intralesional | 1 | 2013 | 36 | 0.030 |
Why?
| | Protein Binding | 1 | 2020 | 2261 | 0.020 |
Why?
| | Hospitals, Veterans | 1 | 1994 | 256 | 0.020 |
Why?
| | Salicylates | 1 | 2013 | 29 | 0.020 |
Why?
| | Urinalysis | 1 | 2013 | 81 | 0.020 |
Why?
| | Long QT Syndrome | 1 | 2013 | 68 | 0.020 |
Why?
| | Nursing Staff, Hospital | 1 | 1994 | 156 | 0.020 |
Why?
| | Hemoglobins | 1 | 1994 | 376 | 0.020 |
Why?
| | Therapeutic Irrigation | 1 | 2012 | 70 | 0.020 |
Why?
| | Iron | 1 | 1994 | 355 | 0.020 |
Why?
| | Receptors, Opioid, mu | 1 | 2012 | 68 | 0.020 |
Why?
| | Agranulocytosis | 1 | 2011 | 30 | 0.020 |
Why?
| | Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2011 | 8 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2011 | 63 | 0.020 |
Why?
| | Leukoencephalopathies | 1 | 2011 | 24 | 0.020 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2012 | 162 | 0.020 |
Why?
| | Computer Simulation | 1 | 2015 | 1032 | 0.020 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2011 | 131 | 0.020 |
Why?
| | Toothache | 1 | 2010 | 5 | 0.020 |
Why?
| | Insulin Resistance | 1 | 2019 | 1255 | 0.020 |
Why?
| | Fluid Therapy | 1 | 2012 | 148 | 0.020 |
Why?
| | Models, Theoretical | 1 | 1994 | 586 | 0.020 |
Why?
| | Quality of Health Care | 1 | 2015 | 649 | 0.020 |
Why?
| | Immunoassay | 1 | 2011 | 112 | 0.020 |
Why?
| | Drug Administration Routes | 1 | 2010 | 41 | 0.020 |
Why?
| | Disease Outbreaks | 1 | 2014 | 423 | 0.020 |
Why?
| | Insurance Coverage | 1 | 2012 | 236 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2010 | 200 | 0.020 |
Why?
| | Neurologic Examination | 1 | 2010 | 129 | 0.020 |
Why?
| | Patient Education as Topic | 1 | 1994 | 791 | 0.020 |
Why?
| | Age Distribution | 1 | 2010 | 395 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2012 | 618 | 0.020 |
Why?
| | Intestines | 1 | 2012 | 354 | 0.020 |
Why?
| | Kidney Failure, Chronic | 1 | 1994 | 596 | 0.020 |
Why?
| | Safety | 1 | 2010 | 352 | 0.020 |
Why?
| | Regression Analysis | 1 | 2010 | 1003 | 0.020 |
Why?
| | Precision Medicine | 1 | 2012 | 450 | 0.020 |
Why?
| | Ethanol | 1 | 2012 | 626 | 0.020 |
Why?
| | Seasons | 1 | 2010 | 547 | 0.020 |
Why?
| | Bilirubin | 1 | 2007 | 87 | 0.020 |
Why?
| | Disease Management | 1 | 2011 | 639 | 0.020 |
Why?
| | Pulse | 1 | 2006 | 27 | 0.020 |
Why?
| | Genotype | 1 | 2012 | 1837 | 0.020 |
Why?
| | Blastomycosis | 1 | 2006 | 11 | 0.020 |
Why?
| | Contraindications | 1 | 2006 | 84 | 0.020 |
Why?
| | Clinical Competence | 1 | 2014 | 1226 | 0.020 |
Why?
| | Biopsy, Fine-Needle | 1 | 2006 | 70 | 0.020 |
Why?
| | Amyloidosis | 1 | 2006 | 45 | 0.010 |
Why?
| | Metabolomics | 1 | 2012 | 721 | 0.010 |
Why?
| | Coronary Circulation | 1 | 2006 | 135 | 0.010 |
Why?
| | European Union | 1 | 2005 | 11 | 0.010 |
Why?
| | Electric Countershock | 1 | 2006 | 116 | 0.010 |
Why?
| | Fever | 1 | 2007 | 311 | 0.010 |
Why?
| | Disaster Planning | 1 | 2006 | 98 | 0.010 |
Why?
| | Emergencies | 1 | 2006 | 172 | 0.010 |
Why?
| | Infant, Newborn | 2 | 2007 | 6362 | 0.010 |
Why?
| | Administration, Inhalation | 1 | 2006 | 592 | 0.010 |
Why?
| | United States Food and Drug Administration | 1 | 2005 | 200 | 0.010 |
Why?
| | Pharmaceutical Preparations | 1 | 2006 | 170 | 0.010 |
Why?
| | Up-Regulation | 1 | 2007 | 863 | 0.010 |
Why?
| | Renal Insufficiency | 1 | 2006 | 167 | 0.010 |
Why?
| | Swine | 1 | 2006 | 843 | 0.010 |
Why?
| | Mice, Inbred ICR | 1 | 2004 | 113 | 0.010 |
Why?
| | Brain Injuries | 1 | 2009 | 506 | 0.010 |
Why?
| | Phenotype | 1 | 2012 | 3183 | 0.010 |
Why?
| | Lupus Nephritis | 1 | 2004 | 71 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2004 | 1054 | 0.010 |
Why?
| | Papillary Muscles | 1 | 2001 | 13 | 0.010 |
Why?
| | Models, Cardiovascular | 1 | 2001 | 197 | 0.010 |
Why?
| | Blood Pressure | 1 | 2006 | 1751 | 0.010 |
Why?
| | Miosis | 1 | 1999 | 4 | 0.010 |
Why?
| | Pupil | 1 | 1999 | 22 | 0.010 |
Why?
| | Hemodynamics | 1 | 2004 | 1116 | 0.010 |
Why?
| | Chronic Disease | 1 | 2004 | 1826 | 0.010 |
Why?
| | Algorithms | 1 | 2004 | 1843 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2001 | 2522 | 0.010 |
Why?
| | Rats | 1 | 2001 | 5609 | 0.010 |
Why?
| | Neoplasms | 1 | 2006 | 2902 | 0.010 |
Why?
|
|
Heard's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|